[ad_1]

PARIS & SAN FRANCISCO–(BUSINESS WIRE)–Regulatory News:

SpineGuard (Paris:ALSGD) (FR0011464452 – ALSGD), an innovative company
that deploys its DSG® real time digital technology for surgical guidance
intended to secure and streamline skeletal implant placement, announced
today the publication of a patent application for using its DSG sensing
technology to provide real time in-situ feedback to robotic surgical
guidance platforms.

The measurement of the electrical conductivity of tissues is used to
prevent breaches through the bone cortex that if not detected could
create dramatic surgical complications. A patent application was filed
in France in October 2017 and is now being extended internationally via
the PCT (Patent Cooperation Treaty) procedure. The patent describes
means to implement the DSG sensing technology to guide and enhance the
safety of surgical assistance robotic platforms and is the result of the
collaboration between SpineGuard and ISIR (Institut des Systèmes
Intelligents et de Robotique). The joined applicants are SpineGuard,
Université Pierre et Marie Curie (now Sorbonne University), INSERM
(Institut National de la Santé et de la Recherche Médicale and CNRS
(Centre National de la Recherche Scientifique).

Stéphane Bette, CEO and co-founder of SpineGuard, said: “We
are thrilled by the ongoing development using DSG technology to feed
robots with meaningful real-time in-situ information from the tissues
that no one else can provide and is radiation-free. This first patent
application in robotics is the first step in the development of
continuous innovations in robotics from our collaboration with the ISIR
lab of Sorbonne University. IP is a crucial component of the enterprise
value of SpineGuard and a key asset in our search for industry partners
to implement the technology adapted to their vision and platforms.”

Guillaume Morel, Professor at the Sorbonne University, adds: “It
is critical that our partners can create value from the results of our
collaborative efforts. That is why we contractually offered to
SpineGuard to purchase the exclusive rights of exploitation in their
application field for this shared IP. SpineGuard was thereby granted the
assurance of the creation of valuable assets, and financial visibility,
as soon as our agreement was signed. That is the basis of a serene and
secured collaboration. On the technology front, this patent application
is a significant first step, it entails the general principle of
coupling the robotic guidance with the DSG measurement. The satisfying
results we obtained very quickly enabled us to file for this first
patent application and ongoing developments confirm the promises. I am
confident that other patents will follow to allow SpineGuard to deploy
its technology in a broader context of surgical gesture assistance by
numerical and robotic means.”

About SpineGuard®

Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane
Bette, SpineGuard is an innovative company deploying its proprietary
real-time digital technology DSG® (Dynamic Surgical Guidance) to secure
and streamline the placement of implants in the skeleton. SpineGuard
designs, develops and markets medical devices that have been used in
over 70,000 surgical procedures worldwide. Fourteen studies published in
peer-reviewed scientific journals have demonstrated the multiple
benefits DSG® offers to patients, surgeons, surgical staff and
hospitals. Building on these solid fundamentals and several strategic
partnerships, SpineGuard has expanded its technology platform in a
disruptive innovation: the « smart » pedicle screw launched late 2017
and is broadening the scope of applications in dental implantology and
surgical robotics. DSG® was co-invented by Maurice Bourlion, Ph.D.,
Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer.

For further information, visit www.spineguard.com

Disclaimer

The SpineGuard securities may not be offered or sold in the United
States as they have not been and will not be registered under the
Securities Act or any United States state securities laws, and
SpineGuard does not intend to make a public offer of its securities in
the United States. This is an announcement and not a prospectus, and the
information contained herein does and shall not constitute an offer to
sell or the solicitation of an offer to buy, nor shall there be any sale
of the securities referred to herein in the United States in which such
offer, solicitation or sale would be unlawful prior to registration or
exemption from registration.

[ad_2]

Source link